Skip to content

Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol

Sagnik Bhattacharyya, Paolo Fusar‐poli, Stefan Borgwardt, Rocío Martín‐Santos, Chiara Nosarti, C. O’Carroll, Paul Allen, Marc L. Seal, Paul C. Fletcher, José A. Crippa, Vincent Giampietro, Andrea Mechelli, Zerrin Atakan, Philip Mcguire

Archives of General Psychiatry April 1, 2009 DOI: 10.1001/archgenpsychiatry.2009.17 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Placebo-controlled Double-blind Peer reviewed
Sample size 15
Population Healthy, native English-speaking, right-handed men of white race/ethnicity who had used cannabis 15 times or less and had minimal exposure to other illicit drugs
Interventions Delta9-tetrahydrocannabinol Cannabidiol Placebo
Dose 10 mg Delta9-THC, 600 mg cannabidiol
Duration Single-dose sessions with no specified follow-up
Topics Anxiety Cannabis CBD
Keywords Sedation Verbal learning Placebo Audiology Psychosis Schizophrenia object-oriented programming Cognition Anesthesia Cannabinoid
Citations 250
Key findings Delta9-THC increased psychotic symptoms and altered parahippocampal and ventrostriatal brain activation during verbal learning, while cannabidiol had no significant effects.

Abstract

CONTEXT: Cannabis sativa use can impair verbal learning, provoke acute psychosis, and increase the risk of schizophrenia. It is unclear where C. sativa acts in the human brain to modulate verbal learning and to induce psychotic symptoms.

Objectives: To investigate the effects of 2 main psychoactive constituents of C. sativa, Delta9-tetrahydrocannabinol (Delta9-THC) and cannabidiol, on regional brain function during verbal paired associate learning.

Design: Subjects were studied on 3 separate occasions using a block design functional magnetic resonance imaging paradigm while performing a verbal paired associate learning task. Each imaging session was preceded by the ingestion of Delta9-THC (10 mg), cannabidiol (600 mg), or placebo in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject design.

Setting: University research center.

Participants: Fifteen healthy, native English-speaking, right-handed men of white race/ethnicity who had used C. sativa 15 times or less and had minimal exposure to other illicit drugs in their lifetime. MAIN OUTCOME MEASURES: Regional brain activation (blood oxygen level-dependent response), performance in a verbal learning task, and objective and subjective ratings of psychotic symptoms, anxiety, intoxication, and sedation.

Results: Delta9-Tetrahydrocannabinol increased psychotic symptoms and levels of anxiety, intoxication, and sedation, whereas no significant effect was noted on these parameters following administration of cannabidiol. Performance in the verbal learning task was not significantly modulated by either drug. Administration of Delta9-THC augmented activation in the parahippocampal gyrus during blocks 2 and 3 such that the normal linear decrement in activation across repeated encoding blocks was no longer evident. Delta9-Tetrahydrocannabinol also attenuated the normal time-dependent change in ventrostriatal activation during retrieval of word pairs, which was directly correlated with concurrently induced psychotic symptoms. In contrast, administration of cannabidiol had no such effect.

Conclusion: The modulation of mediotemporal and ventrostriatal function by Delta9-THC may underlie the effects of C. sativa on verbal learning and psychotic symptoms, respectively.

In the evidence

This study is part of the evidence base for 3 syntheses in the library. Here is how each one recorded it.

  • THC increased anxiety, psychotic symptoms, intoxication, and sedation, whereas CBD had no significant effect on these measures.

    Synthesized

  • Cannabidiol had no significant effects on psychotic symptoms, anxiety, intoxication, sedation, or brain activation during verbal learning.

    Synthesized

  • This RCT found that THC increased psychotic symptoms and altered parahippocampal and ventrostriatal brain activation during verbal learning, while CBD had no significant effects.

    Synthesized

Comparable studies

Other randomized controlled trials on cannabis for anxiety, most cited first.

Study Year Design Participants
Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing Healthy, English-native, right-handed men who had used cannabis 15 times or less in... 2009 Double-blind, randomized, placebo-controlled crossover trial n = 15
Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol Healthy subjects 2009 Randomized controlled trial n = 15
Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis Healthy recreational cannabis users 2022 Randomized controlled trial, within-subjects n = 26
Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity Regular drug users 2015 Three-way crossover study n = 122
Effects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination. Participants who identify with a racial, ethnic, gender, or sexual identity that is... 2025 Randomized controlled trial n = 172

Explore topics

By condition and practice